Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer

IDrugs

Volumn 12, Issue 5, 2009, Pages 302-308

  Baron, A T ^a   Wilken, J A ^a   Haggstrom, D E ^a   Goodrich, S T ^a   Maihle, N J ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIRUBICIN; ERLOTINIB; ESTROGEN RECEPTOR; FADROZOLE; GEFITINIB; GEMCITABINE; ISOPROTEIN; LAPATINIB; LETROZOLE; MEGESTROL; METHOTREXATE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN TYROSINE KINASE; TAMOXIFEN; THALIDOMIDE; TRASTUZUMAB; TUMOR MARKER; UNINDEXED DRUG; VASCULOTROPIN;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARCINOGENESIS; CLINICAL TRIAL; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; THERAGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SOLUBILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 67649371211     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun (2004) 319(1):1-11.
2. Hynes NE, Lane HA: ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer (2005) 5(5):341-354.
3. Lafky JM, Greenewood TM, Baron AT, Boardman CH, Cora EM, Maihle NJ: Soluble ErbB receptors (sEGFR/sErbBs): Serum biomarker in breast and ovarian cancer. In: Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK (Eds), American Association for Clinical Chemistry Inc, Washington DC, USA (2002):427-431.
4. Brandt-Rauf PW: The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutat Res (1995) 333(1-2):203-208.
5. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H et al: EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res (2002) 107:247-258.
6. Lafky JM, Wilken JA, Baron AT, Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta (2008) 1785(2):232-265.
7. Santarpia M, Altavilla G, Salazar F, Tarón M, Rosell R: From the bench to the bed: Individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol (2006) 8(2):71-76.
8. Baselga J: Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist (2002) 7(Suppl 4):2-8.
9. Vourlekis JS, Szabo E: Use of markers for the detection and treatment of lung cancer. Dis Markers (2004) 20(2):71-85.
10. Jimeno A, Hidalgo M: Blockade of epidermal growth factor receptor (EGFR) activity. Crit Rev Oncol Hematol (2005) 53(3):179-192.